News & Events
May 2, 2019
C-Path, CDISC Release Therapeutic Area Standard to Drive Research Forward for Clostridium Difficile Associated DiarrheaTUCSON, Ariz. and AUSTIN, May 2, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Therapeutic Area Standard, which describes how to use CDISC standards to represent data in research studies pertaining to Clostridium difficile associated diarrhea (CDAD). The standard, released in the form of a......
April 16, 2019
C-Path, CDISC Develop Therapeutic Area Standard to Foster More Efficient and Meaningful Research for HIVTUCSON, Ariz. and AUSTIN, April 16, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Therapeutic Area Standard that specifies how to structure commonly collected data and outcome measurements in clinical trials for HIV. The standard, released in the form of User Guide for data......
March 21, 2019
C-Path Selects Global Regulatory Affairs Leader as New President and CEO
After a worldwide search, the Critical Path Institute (C-Path) today announced it has appointed Joseph Scheeren, Pharm. D., as its new President and Chief Executive Officer. Scheeren previously served as Senior Advisor Research and Development for Bayer AG and has had a distinguished 36-year career in the pharmaceutical industry having held positions domestically and internationally in drug development and regulatory approval on three continents.
January 17, 2019
Critical Path Institute Celebrates Expanded Operations with Opening of European HeadquartersC-Path in the EU will work to accelerate the development of new therapies through innovative methodologies for endorsement by regulators of pharmaceutical products TUCSON, Ariz., January 17, 2019 — Critical Path Institute (C-Path) is excited to announce the launch of Critical Path Institute, Ltd. (C-Path, Ltd.) in Ireland, a fully-owned subsidiary that will enable C-Path to......
January 8, 2019
Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial ResistanceTUCSON, Ariz., January 8, 2019 — Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and Microbiome Division of the Translational Genomics Research Institute (TGen) — have received a Phase 1 Concept Validation grant from the Flinn Foundation, of $400,000 over 12 months, to develop and pilot a framework enabling the state......